Overview

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

Status:
Terminated
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Aplaviroc